Shots:

• The company has initiated the ORACLE study evaluating Guardant Reveal liquid biopsy test in 1000 patients with early-stage cancer after curative-intent treatment across 11 solid tumor types
• The study will investigate ctDNA status from blood samples using the Guardant Reveal test after treatment end & routine follow-up. The patients will monitor for ~5 yrs. or until distant recurrence
• The study adds in ongoing clinical studies i.e.- COBRA- ACT-3 & PEGASUS to evaluate blood tests for the same indications. The commercially available test showed 91% sensitivity in detecting ctDNA by genomic alterations & methylation which will focus 1st on early-stage CRC & later on additional cancer types

  | Ref: Businesswire | Image: Businesswire